HeartBeam to Participate in the H.C. Wainwright Global Investment Conference May 23-26, 2022
May 18 2022 - 8:31AM
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage
digital healthcare company with a proprietary ECG telemedicine
technology for heart attack detection, announced today it will
participate virtually in the H.C. Wainwright Global Investment
Conference being held in-person and virtually May 23 – 26,
2022.
HeartBeam Chief Executive Officer and Founder Branislav Vajdic,
PhD, Chief Financial Officer Rick Brounstein, and Chief Business
Officer Jon Hunt, PhD, will conduct 30-minute video one-on-one
meetings during the conference.
Chief Business Officer Jon Hunt, PhD, will deliver the Company’s
virtual presentation which can be viewed on-demand via the webcast
link below and will also be available on the HeartBeam investor
relations website at ir.heartbeam.com. The presentation webcast
will be available on-demand through August 22, 2022.
H.C. Wainwright Global Investment Conference Date: May 23
– 26, 2022 Presentation Time: Available on-demand beginning May 24,
2022 at 7:00 am ET (4:00 am PT) Webcast:
https://journey.ct.events/view/1f138c01-ce9e-44dd-af68-cb3f01d3cad6
Format: Virtual 1x1’s and Virtual Presentations Speaker: Jon Hunt,
PhD, Chief Business Officer Conference Website: Click here
For more information on the H.C. Wainwright Global Investment
Conference or to schedule a one-on-one meeting with HeartBeam
management, please contact your conference representative or you
may also email your request to BEAT@mzgroup.us or call Chris Tyson
at (949) 491-8235.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital
healthcare company with proprietary ECG telemedicine technology
that will redefine the way high risk cardiovascular patients are
diagnosed in an ambulatory setting at any time and any place. Its
breakthrough solution employs a reusable, credit card sized, 3D
vector ECG recording device and cloud-based software capable of
assisting a physician in diagnosing a wide range of cardiovascular
disease. HeartBeam is initially focusing on a huge unmet need of
helping diagnose heart attacks in patients outside of a medical
institution. No single lead ECG technology can offer this value to
patients and their physicians. This underserved market is several
times larger than the cardiac arrhythmia detection market based on
the prevalence of patients with coronary artery disease at high
risk of heart attack. For more information, visit
www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are “forward-looking statements.” While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our recently filed Annual Report on Form 10-K for the year ended
December 31, 2021, which can be found on the SEC’s website at
www.sec.gov. We urge you to consider those risks and uncertainties
in evaluating our forward-looking statements. We caution readers
not to place undue reliance upon any such forward-looking
statements, which speak only as of the date made. Except as
otherwise required by the federal securities laws, we disclaim any
obligation or undertaking to publicly release any updates or
revisions to any forward-looking statement contained herein (or
elsewhere) to reflect any change in our expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220518005250/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Sep 2023 to Sep 2024